Scholar Rock (NASDAQ:SRRK) Insider Sells 7,989 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 7,989 shares of Scholar Rock stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $371,728.17. Following the sale, the insider owned 106,929 shares in the company, valued at approximately $4,975,406.37. This represents a 6.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mo Qatanani also recently made the following trade(s):

• On Thursday, January 22nd, Mo Qatanani sold 14,898 shares of Scholar Rock stock. The shares were sold at an average price of $46.71, for a total transaction of $695,885.58.
• On Friday, January 16th, Mo Qatanani sold 8,406 shares of Scholar Rock stock. The stock was sold at an average price of $44.48, for a total transaction of $373,898.88.
• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The stock was sold at an average price of $45.20, for a total transaction of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The shares were sold at an average price of $45.21, for a total value of $6,169,447.02.

Scholar Rock Trading Up 1.6%

NASDAQ:SRRK traded up $0.74 during trading hours on Thursday, hitting $47.70. 960,100 shares of the company were exchanged, compared to its average volume of 1,005,770. The stock has a market capitalization of $4.87 billion, a price-to-earnings ratio of -15.14 and a beta of 0.67. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82. The company has a fifty day simple moving average of $45.12 and a 200 day simple moving average of $38.23. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41.

Wall Street Analysts Forecast Growth

SRRK has been the topic of a number of recent analyst reports. UBS Group started coverage on Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. Barclays increased their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. HC Wainwright upped their price objective on shares of Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Wolfe Research initiated coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price objective for the company. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock presently has an average rating of “Buy” and an average price target of $51.14.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors have recently added to or reduced their stakes in the business. Siren L.L.C. grew its position in shares of Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after buying an additional 1,575,008 shares during the period. Wellington Management Group LLP increased its stake in Scholar Rock by 26.7% in the fourth quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock valued at $253,703,000 after purchasing an additional 1,213,541 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Scholar Rock by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock valued at $228,860,000 after purchasing an additional 280,538 shares during the period. State Street Corp boosted its position in shares of Scholar Rock by 7.2% during the 4th quarter. State Street Corp now owns 4,034,434 shares of the company’s stock worth $177,717,000 after purchasing an additional 271,331 shares in the last quarter. Finally, Orbis Allan Gray Ltd grew its stake in shares of Scholar Rock by 1,034.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after buying an additional 3,126,677 shares during the period. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).